Haloperidol (Haldol)
Category:
Description:
Indications:
-
Psychoses,
Gilles de la Tourette syndrome, severe behavioral problems
-
Hyperactive
children (short term)
-
Prolonged
parenteral neuroleptic therapy for chronic schizophrenia (decanoate)
Contraindications:
Precautions:
-
Pregnancy
category C; has been used for hyperemesis gravidarum, chorea
gravidarum, and manic depressive illness during pregnancy; excreted in
breast milk; effect on nursing infant unknown, but may be of concern
-
Elderly,
severe cardiac disorders, seizure disorder
-
Hepatic
dysfunction, child < 3 years, alcohol withdrawal
-
Abrupt
withdrawal, glaucoma
Adverse
Reactions (Side Effects):
-
CNS:
agitation, anxiety, catatonic-like behavioral states, confusion,
depression, drowsiness, EPS (pseudoparkinsonism, akathisia, dystonia,
tardive dyskinesia), euphoria, exacerbation of psychotic symptoms
including hallucinations, headache, lethargy, neuroleptic malignant
syndrome, restlessness, seizures, vertigo
-
CV:
ECG changes, hypertension, hypotension, tachycardia
-
EENT:
blurred vision, cataracts, dry eyes, glaucoma, retinopathy
-
GI:
anorexia, constipation, diarrhea, dry mouth, dyspepsia,
hypersalivation, nausea, vomiting
-
GU:
priapism, urinary retention
-
HEME:
agranulocytosis, anemia, leukocytosis, minimal decreases in red blood
cell counts, transient leukopenia
-
METAB:
breast engorgement, gynecomastia, hyperglycemia, hyperprolactinemia,
impotence, increased libido, lactation, mastalgia, menstrual
irregularities
-
RESP:
bronchospasm, increased depth of respiration, laryngospasm
-
SKIN:
diaphoresis, loss of hair, isolated cases of photosensitivity,
maculopapular and acneiform skin reactions
|
Dosage:
Administered
orally and intramuscularly
-
Adult:
-
Psychosis/Tourette’s
syndrome: PO 0.5-5mg 2-3 times daily initially depending on
severity of condition, dose is increased to desired dose, max
100mg daily; IM 2-5mg every 1-8 hours
-
Chronic
schizophrenia: IM 10-15 times the individual patient’s
stabilized PO dose every 4 weeks (decanoate)
-
Child
3-12 years:
-
Psychosis: PO/IM 0.05-0.15 mg/kg/day in 2-3 divided doses
-
Tourette’s
syndrome: PO 0.05-0.075 mg/kg/day in 2-3 divided doses
-
Hyperactivity: PO 0.05-0.075 mg/kg/day in 2-3 divided doses
Special
considerations:
Do
not mix liquid formulation with coffee or tea
Use
calibrated dropper
Take
with food or milk
Arise
slowly from reclining position
Do
not discontinue abruptly
Use
a sunscreen during sun exposure to prevent burns
Take
special precautions to stay cool in hot weather
Observe
closely for signs of tardive dyskinesia
|
Home
· Military Medicine
· Sick Call · Basic Exams
· Medical Procedures
· Lab and X-ray · The Pharmacy
· The Library · Equipment
· Patient Transport
· Medical Force
Protection · Operational Safety · Operational
Settings · Special
Operations · Humanitarian
Missions · Instructions/Orders · Other Agencies · Video Gallery
· Forms · Web Links · Acknowledgements
· Help · Feedback Approved for public release;
Distribution is unlimited. The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.
Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.
Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300 |
Operational Medicine
Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
January 1, 2001 |
United States Special Operations
Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323 |
*This web version is provided by The Brookside Associates, LLC. It contains
original contents from the official US Navy NAVMED P-5139, but has been
reformatted for web access and includes advertising and links that were not
present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the
Department of the Navy or the Department of Defense. The presence of any
advertising on these pages does not constitute an endorsement of that product or
service by either the US Department of Defense or the Brookside Associates. The
Brookside Associates is a private organization, not affiliated with the United
States Department of Defense.
© 2015, Brookside Associates, LLC. All rights reserved
Other Brookside Products
|
|